Focused Consolidator: bioMerieux

As its traditional market in microbiology matures, bioMerieux is tryiing to branch out into broader areas of infectious diseases. But it is confronting a tough environment with lots of competition and rapid consolidation

By Wendy Diller

Alain Merieux, the owner, CEO, and chairman of bioMerieux SA , likes to say that he is on good...

More from Global Vision

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.